Most in vitro RSV neutralizing antibodies in human sera are directed against the prefusion conformation, but due to its instability the prefusion conformation has a propensity to prematurely refold into the stable postfusion conformation, both in solution and on the surface of the virions. An RSV F protein that has both high expression levels and maintains a stable prefusion conformation would, therefore, be a promising subunit vaccine candidate against RSV. To facilitate the RSV-related research, drug trials and vaccine development,a rapid and effective assay kit detecting the specific levels of HRSV Post-Fusion glycoprotein F0 is urgently needed to accelerate the development of RSV vaccines.
